tiprankstipranks
Advertisement
Advertisement
FDA announces availability of final guidance for psychedelic drug research
PremiumThe FlyFDA announces availability of final guidance for psychedelic drug research
18d ago
VA, HHS sign MOU to improve cooperation on psychedelic drug trials
Premium
The Fly
VA, HHS sign MOU to improve cooperation on psychedelic drug trials
20d ago
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
Premium
The Fly
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
20d ago
Compass Pathways price target raised to $21 from $14 at Stifel
PremiumThe FlyCompass Pathways price target raised to $21 from $14 at Stifel
25d ago
Wolfe Research says Compass Pathways pullback an attractive entry point
Premium
The Fly
Wolfe Research says Compass Pathways pullback an attractive entry point
26d ago
Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch
Premium
Ratings
Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch
26d ago
Compass Pathways reports positive Phase 3 depression results
PremiumCompany AnnouncementsCompass Pathways reports positive Phase 3 depression results
26d ago
Psychedelic: Helus Pharma reports FY26 financial results
Premium
The Fly
Psychedelic: Helus Pharma reports FY26 financial results
1M ago
Compass Pathways price target raised to $20 from $18 at Canaccord
Premium
The Fly
Compass Pathways price target raised to $20 from $18 at Canaccord
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100